Advertisement

Der Urologe

, Volume 52, Issue 9, pp 1207–1224 | Cite as

Urinzytologie – Update 2013

Eine systematische Übersicht der neueren Literatur
  • M. BöhmEmail author
  • F. vom Dorp
  • M. Schostak
  • O.W. Hakenberg
  • für den Arbeitskreis Urinzytologie der DGU (Deutsche Gesellschaft für Urologie)
Übersichten

Zusammenfassung

Die Urinzytologie ist ein wesentliches Element bei der Diagnose und Nachsorge von Urothelkarzinomen und findet sich in den meisten diesbezüglichen Leitlinien. Uringebundene Marker werden konkurrierend oder als Ergänzung propagiert. Auch bei der Diagnostik benigner Erkrankungen hat die Urinzytologie Bedeutung. In dieser systematischen Übersicht wird die aktuelle Literatur zur Urinzytologie seit 2010 dargestellt und diskutiert.

Schlüsselwörter

Urothelkarzinom Marker, uringebundene Molekulare Analyse Urinmarker 

Urine cytology – update 2013

A systematic review of recent literature

Abstract

Urine cytology is an important element of the diagnosis and follow-up of urothelial carcinomas and is recommended in most relevant guidelines. Urine-based marker systems are advocated as an adjunct to or a replacement of urine cytology. Urine cytology also has its place in the diagnosis of benign diseases. This systematic review describes and discusses the literature on urine cytology published since 2010.

Keywords

Bladder cancer Markers, urinary Molecular analysis Urothelial carcinoma 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt. M. Böhm, F. vom Dorp, M. Schostak und O.W. Hakenberg geben an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Abdullgaffar B, Kamal MO, Khalid M et al (2010) Can kidney posttransplant lymphoproliferative disorder be detected in voided urine? A case report. Acta Cytol 54:221–224PubMedCrossRefGoogle Scholar
  2. 2.
    Adhya AK, Dey P (2010) Cytologic detection of urinary tract tuberculosis. Acta Cytol 54:653–654PubMedGoogle Scholar
  3. 3.
    Agrawal U, Mishra AK, Salgia P et al (2011) Role of tumor suppressor and angiogenesis markers in prediction of recurrence of non muscle invasive bladder cancer. Pathol Oncol Res 17:91–101PubMedCrossRefGoogle Scholar
  4. 4.
    Aharony S, Baniel J, Yossepowitch O (2011) Clinically unconfirmed positive urinary cytology: diagnostic implications and oncological outcomes. BJU Int 108:179–183CrossRefGoogle Scholar
  5. 5.
    Ahn JS, Kim HS, Chang SG et al (2011) The clinical usefulness of nuclear matrix protein-22 in patients with atypical urine cytology. Korean J Urol 52:603–606PubMedCrossRefGoogle Scholar
  6. 6.
    Ajit D, Dighe S, Desai S (2010) Has urine cytology a role to play in the era of fluorescence in situ hybridization? Acta Cytol 54:1118–1122PubMedGoogle Scholar
  7. 7.
    Al-Maghrebi M, Kehinde EO, Kapila K et al (2012) Urinary survivin mRNA expression and urinary nuclear matrix protein 22 BladderChek® and urine cytology in the detection of transitional cell carcinoma of the bladder. Med Princ Pract 21:295–297PubMedCrossRefGoogle Scholar
  8. 8.
    Alameda F, Juanpere N, Pijuan L et al (2012) Value of p16(INK4a) in the diagnosis of low-grade urothelial carcinoma of the urinary bladder in urinary cytology. Cancer Cytopathol 120:276–282PubMedCrossRefGoogle Scholar
  9. 9.
    Albadine R, Schultz L, Illei P et al (2010) PAX8 (+)/p63 (−) immunostaining pattern in renal collecting duct carcinoma (CDC): a useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract. Am J Surg Pathol 34:965–969PubMedCrossRefGoogle Scholar
  10. 10.
    Ardelt P, Grunemay N, Strehl A et al (2012) LASP-1, a novel urinary marker for detection of bladder cancer. Urol Oncol (Epub ahead of print). DOI 10.1016/j.urolonc.2012.02.002Google Scholar
  11. 11.
    Arora SK, Dey P, Saikia UN (2010) Micronucleus in atypical urothelial cells. Diagn Cytopathol 38:811–813PubMedCrossRefGoogle Scholar
  12. 12.
    Arora SK, Gupta N, Nijhawan R et al (2010) Epithelioid cell granulomas in urine cytology smears: Same cause, different implications. Diagn Cytopathol 38:765–767PubMedGoogle Scholar
  13. 13.
    Arora VK, Sarungbam J, Bhatia A et al (2010) Usefulness of NMP22 as an adjunct to a typical urine cytology and low-grade urothelial carcinoma. Diagn Cytopathol 38:788–790PubMedCrossRefGoogle Scholar
  14. 14.
    Ayala De La Pena F, Kanasaki K, Kanasaki M et al (2011) Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma. J Biol Chem 286:20778–20787CrossRefGoogle Scholar
  15. 15.
    Azarpira N, Vasei M, Rasekhi A (2012) Plasma cell tumors with neurologic symptoms: cytological findings. Diagn Cytopathol 40:248–251PubMedCrossRefGoogle Scholar
  16. 16.
    Babjuk M, Oosterlinck W, Sylvester R et al (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 Update. Eur Urol 59:997–1008PubMedCrossRefGoogle Scholar
  17. 17.
    Bangma CH, Loeb S, Busstra M et al (2013) Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers. Eur Urol 64:41–47PubMedCrossRefGoogle Scholar
  18. 18.
    Bantis A, Zissimopoulos A, Sountoulides P et al (2010) Tissue polypeptide antigen in the follow-up of patients with urinary bladder cancer compared with conventional urine cytology. Hell J Nucl Med 13:213–217PubMedGoogle Scholar
  19. 19.
    Behnsawy HM, Miyake H, Abdalla MA et al (2011) Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: correlation with intravesical recurrence following transurethral resection. Urol Oncol 29:495–501PubMedCrossRefGoogle Scholar
  20. 20.
    Beiske K, Burchill SA, Cheung IY et al (2009) Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. Br J Cancer 100:1627–1637PubMedCrossRefGoogle Scholar
  21. 21.
    Bellmunt J, Orsola A, Wiegel T et al (2011) Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):45–49Google Scholar
  22. 22.
    Blick CG, Nazir SA, Mallett S et al (2012) Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic. BJU Int 110:84–94PubMedCrossRefGoogle Scholar
  23. 23.
    Bodoor K, Ghabkari A, Jaradat Z et al (2010) FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population. Cancer Epidemiol 34:724–732PubMedCrossRefGoogle Scholar
  24. 24.
    Bolenz C, Lotan Y (2010) Translational research in bladder cancer: from molecular pathogenesis to useful tissue biomarkers. Cancer Biol Ther 10:407–415PubMedCrossRefGoogle Scholar
  25. 25.
    Bolenz C, West AM, Ortiz N et al (2011) Urinary cytology for the detection of urothelial carcinoma of the bladder-a flawed adjunct to cystoscopy? Urol Oncol 31(3):366–371PubMedGoogle Scholar
  26. 26.
    Boorjian SA, Kim SP, Weight CJ et al (2011) Risk factors and outcomes of urethral recurrence following radical cystectomy. Eur Urol 60:1266–1272PubMedCrossRefGoogle Scholar
  27. 27.
    Boutonnat J, Pinel N, Janbon B (2009) Urinary cytology and polyomavirus infection: a major stake for patients. Ann Pathol 29(Spec No 1):116–117CrossRefGoogle Scholar
  28. 28.
    Bravaccini S, Casadio V, Gunelli R et al (2011) Combining cytology, TRAP assay, and FISH analysis for the detection of bladder cancer in symptomatic patients. Ann Oncol 22:2294–2298PubMedCrossRefGoogle Scholar
  29. 29.
    Brems-Eskildsen AS, Zieger K, Toldbod H et al (2010) Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts. BMC Cancer 10:646PubMedCrossRefGoogle Scholar
  30. 30.
    Brien JC, Shariat SF, Herman MP et al (2010) Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol 184:69–73PubMedCrossRefGoogle Scholar
  31. 31.
    Bubendorf L, Dalquen P, Savic S (2009) Zytologie der ableitenden Harnwege: Zwischen Zweifel und Gewissheit. Pathologe 30(Suppl 2):173–178PubMedCrossRefGoogle Scholar
  32. 32.
    Burger M, vom Dorp F (2011) Nutzung von Markersystemen in der Behandlung des Harnblasenkarzinoms. Urologe 50:303–308PubMedCrossRefGoogle Scholar
  33. 33.
    Caraway NP, Katz RL (2010) A review on the current state of urine cytology emphasizing the role of fluorescence in situ hybridization as an adjunct to diagnosis. Cancer Cytopathol 118:175–183PubMedCrossRefGoogle Scholar
  34. 34.
    Caraway NP, Khanna A, Fernandez RL et al (2010) Fluorescence in situ hybridization for detecting urothelial carcinoma: a clinicopathologic study. Cancer Cytopathol 118:259–268PubMedCrossRefGoogle Scholar
  35. 35.
    Castelino-Prabhu S, Ali SZ (2010) Osteoclast-rich undifferentiated carcinoma of the urinary tract: cytologic findings and literature review. Diagn Cytopathol 38:364–367PubMedCrossRefGoogle Scholar
  36. 36.
    Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O et al (2010) Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol 28:401–408PubMedCrossRefGoogle Scholar
  37. 37.
    Cha EK, Tirsar LA, Schwentner C et al (2012) Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study. Eur Urol 61:185–192PubMedCrossRefGoogle Scholar
  38. 38.
    Chade DC, Shariat SF, Adamy A et al (2010) Clinical outcome of primary versus secondary bladder carcinoma in situ. J Urol 184:464–469PubMedCrossRefGoogle Scholar
  39. 39.
    Chade DC, Shariat SF, Godoy G et al (2010) Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. J Urol 184:74–80PubMedCrossRefGoogle Scholar
  40. 40.
    Chakera A, Dyar OJ, Hughes E et al (2011) Detection of polyomavirus BK reactivation after renal transplantation using an intensive decoy cell surveillance program is cost-effective. Transplantation 92:1018–1023PubMedGoogle Scholar
  41. 41.
    Chan ES, Ng CF, Hou SM et al (2011) Using urine microscopy and cytology for early detection of bladder cancer in male patients with lower urinary tract symptoms. Int Urol Nephrol 43:289–294PubMedCrossRefGoogle Scholar
  42. 42.
    Chandra A, Griffiths D, Mcwilliam LJ (2010) Best practice: gross examination and sampling of surgical specimens from the urinary bladder. J Clin Pathol 63:475–479PubMedCrossRefGoogle Scholar
  43. 43.
    Chen N, Gong J, Zeng H et al (2011) Value of fluorescence in situ hybridization of urine exfoliative cells in diagnosis of urinary bladder neoplasms. Sichuan Da Xue Xue Bao Yi Xue Ban 42:109–113PubMedGoogle Scholar
  44. 44.
    Cheung IY, Barber D, Cheung N-KV (1998) Detection of microscopic neuroblastoma in marrow by histology, immunocytology, and reverse transcription-PCR of multiple molecular markers. Clin Cancer Res 4:2801–2805PubMedGoogle Scholar
  45. 45.
    Choi HS, Lee SI, Kim DJ et al (2010) Usefulness of the NMP22 BladderChek test for screening and follow-up of bladder cancer. Korean J Urol 51:88–93PubMedCrossRefGoogle Scholar
  46. 46.
    Chou R, Dana T (2010) Screening adults for bladder cancer: a review of the evidence for the U.S. preventive services task force. Ann Intern Med 153:461–468PubMedCrossRefGoogle Scholar
  47. 47.
    Chung BH, Hong YA, Kim HG et al (2012) Clinical usefulness of BK virus plasma quantitative PCR to prevent BK virus associated nephropathy. Transpl Int 25:687–695PubMedCrossRefGoogle Scholar
  48. 48.
    Cimino-Mathews A, Ali SZ (2011) The clinicopathologic correlates of cellular atypia in urinary cytology of ileal neobladders. Acta Cytol 55:449–454PubMedCrossRefGoogle Scholar
  49. 49.
    Cioffi-Lavina M, Chapman-Fredricks J, Gomez-Fernandez C et al (2010) P16 expression in squamous cell carcinomas of cervix and bladder. Appl Immunohistochem Mol Morphol 18:344–347PubMedCrossRefGoogle Scholar
  50. 50.
    Collin-Chavagnac D, Marcais C, Billon S et al (2010) Quantitative loss of heterozygosity analysis for urothelial carcinoma detection and prognosis. Urology 76:515 511–517PubMedCrossRefGoogle Scholar
  51. 51.
    Courtade-Saïdi M, Aziza J, Collin L et al (2010) Les difficultés diagnostiques liées aux Polyomavirus en cytologie urinaire. Ann Pathol 30:176–181PubMedCrossRefGoogle Scholar
  52. 52.
    Crop MJ, De Rijke YB, Verhagen PC et al (2010) Diagnostic value of urinary dysmorphic erythrocytes in clinical practice. Nephron Clin Pract 115:203–212CrossRefGoogle Scholar
  53. 53.
    Dubal SB, Pathuthara S, Ajit D et al (2011) Case report of renal cell carcinoma diagnosed in voided urine confirmed by CD10 immunocytochemistry. Acta Cytol 55:372–376PubMedCrossRefGoogle Scholar
  54. 54.
    Eguchi S, Yamamoto Y, Sakano S et al (2010) The loss of 8p23.3 is a novel marker for predicting progression and recurrence of bladder tumors without muscle invasion. Cancer Genet Cytogenet 200:16–22PubMedCrossRefGoogle Scholar
  55. 55.
    Eissa S, Swellam M, Amin A et al (2011) The clinical relevance of urine-based markers for diagnosis of bladder cancer. Med Oncol 28:513–518PubMedCrossRefGoogle Scholar
  56. 56.
    Eissa S, Swellam M, Shehata H et al (2010) Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer. J Urol 183:493–498PubMedCrossRefGoogle Scholar
  57. 57.
    Eissa S, Zohny SF, Zekri AR et al (2010) Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence. Med Oncol 27:1286–1294PubMedCrossRefGoogle Scholar
  58. 58.
    Elias K, Svatek RS, Gupta S et al (2010) High-risk patients with hematuria are not evaluated according to guideline recommendations. Cancer 116:2954–2959PubMedCrossRefGoogle Scholar
  59. 59.
    Falebita OA, Lee G, Sweeney P (2010) Urine cytology in the evaluation of urological malignancy revisited: is it still necessary? Urol Int 84:45–49PubMedCrossRefGoogle Scholar
  60. 60.
    Feifer AH, Steinberg J, Tanguay S et al (2010) Utility of urine cytology in the workup of asymptomatic microscopic hematuria in low-risk patients. Urology 75:1278–1282PubMedCrossRefGoogle Scholar
  61. 61.
    Feng CC, Wang PH, Guan M et al (2011) Urinary BLCA-4 is highly specific for detection of bladder cancer in Chinese Han population and is related to tumour invasiveness. Folia Biol (Praha) 57:242–247Google Scholar
  62. 62.
    Fernandez-Acenero MJ, Cordova S, Manzarbeitia F et al (2011) Immunohistochemical profile of urothelial and small cell carcinomas of the bladder. Pathol Oncol Res 17:519–523PubMedCrossRefGoogle Scholar
  63. 63.
    Fernández MI, Parikh S, Grossman HB et al (2012) The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer. Urol Oncol 30:821–824PubMedCrossRefGoogle Scholar
  64. 64.
    Fritsche HM, Burger M, Dietmaier W et al (2010) Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder. Am J Clin Pathol 134:597–603PubMedCrossRefGoogle Scholar
  65. 65.
    Gakis G, Kruck S, Stenzl A (2010) Can the burden of follow-up in low-grade noninvasive bladder cancer be reduced by photodynamic diagnosis, perioperative instillations, imaging, and urine markers? Curr Opin Urol 20:388–392PubMedCrossRefGoogle Scholar
  66. 66.
    Gakis G, Schwentner C, Todenhöfer T et al (2012) Current status of molecular markers for prognostication and outcome in invasive bladder cancer. BJU Int 110:233–237PubMedCrossRefGoogle Scholar
  67. 67.
    Galed-Placed I, Valbuena-Ruvira L (2011) Decoy cells and malignant cells coexisting in the urine from a transplant recipient with BK virus nephropathy and bladder adenocarcinoma. Diagn Cytopathol 39:933–937PubMedCrossRefGoogle Scholar
  68. 68.
    Galvan AB, Salido M, Espinet B et al (2011) A multicolor fluorescence in situ hybridization assay: a monitoring tool in the surveillance of patients with a history of non-muscle-invasive urothelial cell carcinoma: a prospective study. Cancer Cytopathol 119:395–403PubMedCrossRefGoogle Scholar
  69. 69.
    Gaston KE, Grossman HB (2010) Proteomic assays for the detection of urothelial cancer. Methods Mol Biol 641:303–323PubMedCrossRefGoogle Scholar
  70. 70.
    Giberti C, Gallo F, Schenone M et al (2010) Early results of urothelial carcinoma screening in a risk population of coke workers: urothelial carcinoma among coke workers. Biomed Environ Sci 23:300–304PubMedCrossRefGoogle Scholar
  71. 71.
    Glatz K, Willi N, Glatz D et al (2006) An international telecytologic quiz on urinary cytology reveals educational deficits and absence of a commonly used classification system. Am J Clin Pathol 126:294–301PubMedCrossRefGoogle Scholar
  72. 72.
    Grabskii AM, Muradian AA, Agaian MA et al (2010) Characteristic of cytopathological changes in urine after extracorporeal shock wave lithotripsy. Georgian Med News:14–18Google Scholar
  73. 73.
    Grossman HB (2010) Are biomarkers for bladder cancer beneficial? J Urol 183:11–12PubMedCrossRefGoogle Scholar
  74. 74.
    Guan H, Rosenthal DL, Erozan YS (2011) Mullerianosis of the urinary bladder: report of a case with diagnosis suggested in urine cytology and review of literature. Diagn Cytopathol 40:997–1001PubMedCrossRefGoogle Scholar
  75. 75.
    Guan H, Tatsas AD, Ali SZ (2012) Signet ring cell carcinoma in urine cytology: cytomorphologic findings and differential diagnosis. Acta Cytol 56:177–182PubMedCrossRefGoogle Scholar
  76. 76.
    Guo B, Che T, Shi B et al (2011) Screening and identification of specific markers for bladder transitional cell carcinoma from urine urothelial cells with suppressive subtractive hybridization and cDNA microarray. Can Urol Assoc J 5:129–137CrossRefGoogle Scholar
  77. 77.
    Hayashi T, Sentani K, Oue N et al (2011) Desmocollin 2 is a new immunohistochemical marker indicative of squamous differentiation in urothelial carcinoma. Histopathology 59:710–721PubMedCrossRefGoogle Scholar
  78. 78.
    Hess J, Tschirdewahn S, Szarvas T et al (2011) Urothelkarzinom der Harnblase: Kombinierte endoskopische und urinzytologische Beurteilung: Lässt es sich sicher einschätzen? Urologe 50:702–705PubMedCrossRefGoogle Scholar
  79. 79.
    Higuchi TT, Fox JA, Husmann DA (2011) Annual endoscopy and urine cytology for the surveillance of bladder tumors after enterocystoplasty for congenital bladder anomalies. J Urol 186:1791–1795PubMedCrossRefGoogle Scholar
  80. 80.
    Hodges KB, Lopez-Beltran A, Emerson RE et al (2010) Clinical utility of immunohistochemistry in the diagnoses of urinary bladder neoplasia. Appl Immunohistochem Mol Morphol 18:401–410PubMedGoogle Scholar
  81. 81.
    Horstmann M, Bontrup H, Hennenlotter J et al (2010) Clinical experience with survivin as a biomarker for urothelial bladder cancer. World J Urol 28:399–404PubMedCrossRefGoogle Scholar
  82. 82.
    Horstmann M, Patschan O, Hennenlotter J et al (2009) Combinations of urine-based tumour markers in bladder cancer surveillance. Scand J Urol Nephrol 43:461–466PubMedCrossRefGoogle Scholar
  83. 83.
    Hosseini J, Golshan AR, Mazloomfard MM et al (2012) Detection of recurrent bladder cancer: NMP22 test or urine cytology? Urol J 9:367–372PubMedGoogle Scholar
  84. 84.
    Huang WT, Li LY, Pang J et al (2012) Fluorescence in situ hybridization assay detects upper urinary tract transitional cell carcinoma in patients with asymptomatic hematuria and negative urine cytology. Neoplasma 59:355–360PubMedCrossRefGoogle Scholar
  85. 85.
    Huber S, Schwentner C, Taeger D et al (2012) Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study. BJU Int 110:699–708PubMedCrossRefGoogle Scholar
  86. 86.
    Humphrey PA (2011) Micropapillary urothelial carcinoma of the urinary tract. J Urol 186:1071–1072PubMedCrossRefGoogle Scholar
  87. 87.
    Humphrey PA (2012) Urothelial carcinoma in situ of the bladder. J Urol 187:1057–1058PubMedCrossRefGoogle Scholar
  88. 88.
    Hüppe P, Wawroschek F (2011) Methodik und aktueller Stellenwert der Mikrohämaturiediagnostik. Urologe 50:287–291PubMedCrossRefGoogle Scholar
  89. 89.
    Iwa N, Ito S, Takegaki Y et al (2013) Cytologic features of sarcomatoid carcinoma of the urinary bladder: A case report. Diagn Cytopathol 41:536–541PubMedCrossRefGoogle Scholar
  90. 90.
    Jacobs BL, Lee CT, Montie JE (2010) Bladder cancer in 2010: how far have we come? CA Cancer J Clin 60:244–272PubMedCrossRefGoogle Scholar
  91. 91.
    Jang SM, Na W, Jun YJ et al (2010) Primary vesical actinomycosis diagnosed by routine urine cytology. Acta Cytol 54:658–659PubMedGoogle Scholar
  92. 92.
    Jazaerly T, Jaratli H, Jacques SM et al (2011) Small cell carcinoma of the ovary presenting in a urine cytology specimen: a case report. Acta Cytol 55:291–295PubMedCrossRefGoogle Scholar
  93. 93.
    Johannes JR, Nelson E, Bibbo M et al (2010) Voided urine fluorescence in situ hybridization testing for upper tract urothelial carcinoma surveillance. J Urol 184:879–882PubMedCrossRefGoogle Scholar
  94. 94.
    Jovanovic M, Soldatovic I, Janjic A et al (2011) Diagnostic value of the nuclear matrix protein 22 test and urine cytology in upper tract urothelial tumors. Urol Int 87:134–137PubMedCrossRefGoogle Scholar
  95. 95.
    Jungmann O, Zumbé J (2009) Auf Spurensuche im Urin. Uro-News 9:29–36Google Scholar
  96. 96.
    Kakiashvili DM, van Rhijn BW, Trottier G et al (2011) Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guerin treatment. BJU Int 107:540–546PubMedCrossRefGoogle Scholar
  97. 97.
    Kamat AM, Dickstein RJ, Messetti F et al (2012) Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guerin therapy for bladder cancer: results of a prospective trial. J Urol 187:862–867PubMedCrossRefGoogle Scholar
  98. 98.
    Karl A, Tritschler S, Staehler M et al (2011) Bladder cancer–symptoms and diagnosis. MMW Fortschr Med 153:38–42Google Scholar
  99. 99.
    Karnwal A, Venegas R, Shuch B et al (2010) The role of fluorescence in situ hybridization assay for surveillance of non-muscle invasive bladder cancer. Can J Urol 17:5077–5081PubMedGoogle Scholar
  100. 100.
    Kehinde EO, Al-Mulla F, Kapila K et al (2011) Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer. Scand J Urol Nephrol 45:113–121PubMedCrossRefGoogle Scholar
  101. 101.
    Kim TS, Rhew HY, Hwang HY (2011) Pilot study of the clinical significance of serum and urinary her-2/neu protein in bladder cancer patients. Korean J Urol 52:815–818PubMedCrossRefGoogle Scholar
  102. 102.
    Klatte T, Belldegrun AS, Pantuck AJ (2008) The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder. BJU Int 101(Suppl 4):45–48PubMedCrossRefGoogle Scholar
  103. 103.
    Knüchel-Clarke R, Dahl E, Gaisa NT et al (2010) Stand des Wissens zur molekularen Pathologie des Urothelkarzinoms. Pathologe 31(Suppl 2):234–238PubMedCrossRefGoogle Scholar
  104. 104.
    Kompier LC, Lurkin I, van der Aa MN et al (2010) FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 5:13821CrossRefGoogle Scholar
  105. 105.
    Ku JH, Godoy G, Amiel GE et al (2012) Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review. BJU Int 110:630–636PubMedCrossRefGoogle Scholar
  106. 106.
    Kundal VK, Pandith AA, Hamid A et al (2010) Role of NMP22 Bladder Check Test in early detection of bladder cancer with recurrence. Asian Pac J Cancer Prev 11:1279–1282PubMedGoogle Scholar
  107. 107.
    Lai Y, Ye J, Chen J et al (2010) UPK3A: a promising novel urinary marker for the detection of bladder cancer. Urology 76:514–511PubMedCrossRefGoogle Scholar
  108. 108.
    Larre S, Camparo P, Comperat E et al (2011) Diagnostic, staging, and grading of urothelial carcinomas from urine: performance of BCA-1, a mini-array comparative genomic hybridisation-based test. Eur Urol 59:250–257PubMedCrossRefGoogle Scholar
  109. 109.
    Laucirica R, Bentz JS, Souers RJ et al (2010) Do liquid-based preparations of urinary cytology perform differently than classically prepared cases? Observations from the College of American Pathologists Interlaboratory Comparison Program in Nongynecologic Cytology. Arch Pathol Lab Med 134:19–22PubMedGoogle Scholar
  110. 110.
    Laudano MA, Barlow LJ, Murphy AM et al (2010) Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy. Urology 75:134–137PubMedCrossRefGoogle Scholar
  111. 111.
    Leblanc RE, Maleki Z (2013) Herpes simplex viral cytopathic effect in urine cytology. Diagn Cytopathol 41:61–62PubMedCrossRefGoogle Scholar
  112. 112.
    Li HX, Li M, Li CL et al (2010) ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: a prospective study. Anal Quant Cytol Histol 32:45–52PubMedGoogle Scholar
  113. 113.
    Lindemann-Docter K, Gaisa NT, Smeets D et al (2011) Urine markers with special regard to fluorescent in situ hybridization (FISH). Urologe 50:297–302PubMedCrossRefGoogle Scholar
  114. 114.
    Lintula S, Hotakainen K (2010) Developing biomarkers for improved diagnosis and treatment outcome monitoring of bladder cancer. Expert Opin Biol Ther 10:1169–1180PubMedCrossRefGoogle Scholar
  115. 115.
    Loghavi S, Bose S (2011) Polyomavirus infection and urothelial carcinoma. Diagn Cytopathol 39:531–535PubMedCrossRefGoogle Scholar
  116. 116.
    Losell K, Zendehrokh N, Solding I et al (2010) Comparison of liquid-based cytology and conventional filter preparations in urine: a possible serious pitfall. Acta Cytol 54:114–117PubMedCrossRefGoogle Scholar
  117. 117.
    Lotan Y, Shariat SF, Schmitz-Dräger BJ et al (2010) Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol 28:441–448PubMedCrossRefGoogle Scholar
  118. 118.
    Madeb R, Golijanin D, Knopf J et al (2010) Long-term outcome of patients with a negative work-up for asymptomatic microhematuria. Urology 75:20–25PubMedCrossRefGoogle Scholar
  119. 119.
    Mai KT, Teo I, Robertson SJ et al (2009) Immunostaining as a diagnostic aid in cytopathologic study of upper urinary tract urothelial carcinoma. Acta Cytol 53:611–618PubMedCrossRefGoogle Scholar
  120. 120.
    Maia TM, Silva SF, Silva SL et al (2011) Polyomavirus-infected decoy cells in cytocentrifuged urine cytology specimens from renal transplant recipients. Acta Cytol 55:445–448PubMedCrossRefGoogle Scholar
  121. 121.
    Malhotra K, Sharma S (2012) Urine cytology in paroxysmal nocturnal hemoglobinuria. Diagn Cytopathol 40:804–805CrossRefGoogle Scholar
  122. 122.
    Mao L, Schoenberg MP, Scicchitano M et al (1996) Molecular detection of primary bladder cancer by microsatellite analysis. Science 271:659–662PubMedCrossRefGoogle Scholar
  123. 123.
    Marshall VF, Seybolt JF (1977) Early detection but delayed appearance of a bladder tumor. J Urol 118:175–176PubMedGoogle Scholar
  124. 124.
    Martinez-Giron R, Gonzalez-Lopez JR (2012) Uncommon fungal contamination in urine cytology. Diagn Cytopathol 40:234–235PubMedCrossRefGoogle Scholar
  125. 125.
    Matsushima M, Kikuchi E, Hasegawa M et al (2010) Clinical impact of bladder biopsies with TUR-BT according to cytology results in patients with bladder cancer: a case control study. BMC Urol 10:12PubMedCrossRefGoogle Scholar
  126. 126.
    May M, Brookman-Amissah S, Roigas J et al (2010) Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol 57:850–858PubMedCrossRefGoogle Scholar
  127. 127.
    McConkey DJ, Lee S, Choi W et al (2010) Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urol Oncol 28:429–440PubMedCrossRefGoogle Scholar
  128. 128.
    McKnight R, Cohen C, Siddiqui MT (2011) Fascin stain as a potential marker of invasiveness in carcinomas of the urinary bladder: a retrospective study with biopsy and cytology correlation. Diagn Cytopathol 39:635–640PubMedCrossRefGoogle Scholar
  129. 129.
    Mehta T, Sanaei-Ardekani M, Farooqi A et al (2011) The utility of cytodiagnostic urinalysis as a tool to diagnose kidney allograft dysfunction in the era lymphocyte-depleting induction therapy. Transplant Proc 43:3679–3685PubMedCrossRefGoogle Scholar
  130. 130.
    Melicow MM, Hollowell JW (1952) Intra-urothelial cancer: carcinoma in situ, Bowen’s disease of the urinary system: discussion of thirty cases. J Urol 68:763–772PubMedGoogle Scholar
  131. 131.
    Melissourgos ND, Kastrinakis NG, Skolarikos A et al (2005) Cytokeratin-20 immunocytology in voided urine exhibits greater sensitivity and reliability than standard cytology in the diagnosis of transitional cell carcinoma of the bladder. Urology 66:536–541PubMedCrossRefGoogle Scholar
  132. 132.
    Messer J, Shariat SF, Brien JC et al (2011) Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int 108:701–705PubMedGoogle Scholar
  133. 133.
    Metzgeroth G, Kuhn C, Schultheis B et al (2008) Diagnostic accuracy of cytology and immunocytology in carcinomatous effusions. Cytopathology 19:205–211PubMedCrossRefGoogle Scholar
  134. 134.
    Mezzasoma L, Antognelli C, Del Buono C et al (2010) Expression and biological-clinical significance of hTR, hTERT and CKS2 in washing fluids of patients with bladder cancer. BMC Urol 10:17PubMedCrossRefGoogle Scholar
  135. 135.
    Mian C, Mazzoleni G, Vikoler S et al (2010) Fluorescence in situ hybridisation in the diagnosis of upper urinary tract tumours. Eur Urol 58:288–292PubMedCrossRefGoogle Scholar
  136. 136.
    Mihovilovic K, Kardum-Skelin I, Ljubanovic D et al (2010) Urine immunocytology as a noninvasive diagnostic tool for acute kidney rejection: a single center experience. Coll Antropol 34:63–67PubMedGoogle Scholar
  137. 137.
    Mimura A, Sakuma T, Furuta M et al (2010) Sarcomatoid collecting duct carcinoma of kidney diagnosed with urine and renal pelvic lavage cytology. Diagn Cytopathol 38:603–606PubMedGoogle Scholar
  138. 138.
    Mishriki SF, Vint R, Somani BK (2012) Half of visible and half of recurrent visible hematuria cases have underlying pathology: prospective large cohort study with long-term followup. J Urol 187:1561–1565PubMedCrossRefGoogle Scholar
  139. 139.
    Miyamoto H, Brimo F, Schultz L et al (2010) Low-grade papillary urothelial carcinoma of the urinary bladder: a clinicopathologic analysis of a post-World Health Organization/International Society of Urological Pathology classification cohort from a single academic center. Arch Pathol Lab Med 134:1160–1163PubMedGoogle Scholar
  140. 140.
    Mokhtar GA, Al-Dousari M, Al-Ghamedi D (2010) Diagnostic significance of atypical category in the voided urine samples: A retrospective study in a tertiary care center. Urol Ann 2:100–106PubMedCrossRefGoogle Scholar
  141. 141.
    Moll R, Divo M, Langbein L (2008) The human keratins: biology and pathology. Histochem Cell Biol 129:705–733PubMedCrossRefGoogle Scholar
  142. 142.
    Mowatt G, Zhu S, Kilonzo M et al (2010) Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 14:1–331Google Scholar
  143. 143.
    Mu DW, Zhou LQ, Ding Y et al (2010) Clinical utility of fluorescence in situ hybridization improves the sensitivity in the diagnosis of upper urinary tract urothelial carcinoma. Beijing Da Xue Xue Bao 42:381–385PubMedGoogle Scholar
  144. 144.
    Murphy AB, Taylor AK, Nadler RB (2010) Prostatitis: predictive value of post-massage urine leukocyte count for AIP. Nat Rev Urol 7:65–66PubMedCrossRefGoogle Scholar
  145. 145.
    Murphy WM (2006) What’s the trouble with cytology? J Urol 176:2343–2346PubMedCrossRefGoogle Scholar
  146. 146.
    Mustafa M, Pancaroglu K (2011) Urine cytology to evaluate urinary urothelial damage of shock-wave lithotripsy. Urol Res 39:223–227PubMedCrossRefGoogle Scholar
  147. 147.
    Nasterlack M, Feil G, Leng G et al (2011) Das Screening von Harnblasenkarzinomen mittels urinbasierter Tumormarker – Erfahrungen aus der Arbeitsmedizin. Aktuelle Urol 42:128–134PubMedCrossRefGoogle Scholar
  148. 148.
    Nawroth R, Hartmann A, Olbert PJ et al (2011) Blasenkarzinom – Update: Was gab es Neues auf dem Jahreskongress 2010 der Deutschen Gesellschaft fur Urologie in Düsseldorf? Urologe 50:221–226PubMedCrossRefGoogle Scholar
  149. 149.
    Netto GJ (2012) Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? Nat Rev Urol 9:41–51CrossRefGoogle Scholar
  150. 150.
    Niedworok C, Rembrink V, Hakenberg OW et al (2009) Stellenwert der Urinzytologie in der Diagnostik von High-grade-Urotheltumoren. Urologe 48:1018–1024PubMedCrossRefGoogle Scholar
  151. 151.
    Niegisch G, Koch A, Knievel J et al (2010) Signaltransduktion im Urothelkarzinom: Wie genau kennen wir die Ziele für eine zielgerichtete Therapie? Urologe 49:1401–1405PubMedCrossRefGoogle Scholar
  152. 152.
    Nohara T, Sakai A, Fuse H et al (2009) Metastatic malignant melanoma of the urinary bladder: a case report. Nihon Hinyokika Gakkai Zasshi 100:707–711PubMedCrossRefGoogle Scholar
  153. 153.
    Norimatsu Y, Kawanishi N, Shigematsu Y et al (2010) Use of liquid-based preparations in urine cytology: An evaluation of Liqui-PREP and BD SurePath. Diagn Cytopathol 38:702–704PubMedCrossRefGoogle Scholar
  154. 154.
    Odisho AY, Berry AB, Ahmad AE et al (2013) Reflex ImmunoCyt testing for the diagnosis of bladder cancer in patients with atypical urine cytology. Eur Urol 63:936–940PubMedCrossRefGoogle Scholar
  155. 155.
    Offersen BV, Knap MM, Horsman MR et al (2010) Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival. Acta Oncol 49:1283–1287PubMedCrossRefGoogle Scholar
  156. 156.
    Oǧuztüzün S, Sezgin Y, Yazıcı S et al (2011) Expression of glutathione-S-transferases isoenzymes and p53 in exfoliated human bladder cancer cells. Urol Oncol 29:538–544PubMedCrossRefGoogle Scholar
  157. 157.
    Ohsaki H, Hirakawa E, Kagawa K et al (2010) Value of computer-assisted quantitative nuclear morphometry for differentiation of reactive renal tubular cells from low-grade urothelial carcinoma. Cytopathology 21:334–338PubMedCrossRefGoogle Scholar
  158. 158.
    Ohsaki H, Hirakawa E, Kushida Y et al (2010) Can cytological features differentiate reactive renal tubular cells from low-grade urothelial carcinoma cells? Cytopathology 21:326–333PubMedCrossRefGoogle Scholar
  159. 159.
    Ohsaki H, Hirakawa E, Nakamura M et al (2011) Expression of vimentin and high-molecular-weight cytokeratin (clone 34ssE12) in differentiating reactive renal tubular cells from low-grade urothelial carcinoma cells in voided urine. Cytopathology 22:247–252PubMedCrossRefGoogle Scholar
  160. 160.
    Ohsaki H, Hirouchi T, Hayashi N et al (2013) Diagnostic value of urine erythrocyte morphology in the detection of glomerular disease in SurePath liquid-based cytology compared with fresh urine sediment examination. Cytopathology 24:52–57PubMedCrossRefGoogle Scholar
  161. 161.
    Okajima E, Fujimoto H, Mizutani Y et al (2010) Cancer death from non-muscle invasive bladder cancer: report of the Japanese Urological Association of data from the 1999–2001 registry in Japan. Int J Urol 17:905–912PubMedCrossRefGoogle Scholar
  162. 162.
    Oshiro H, Gomi K, Nagahama K et al (2010) Urinary cytologic features of primary large cell neuroendocrine carcinoma of the urinary bladder: a case report. Acta Cytol 54:303–310PubMedCrossRefGoogle Scholar
  163. 163.
    Otto W, Shariat SF, Fritsche HM et al (2011) Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients. World J Urol 29:487–494PubMedCrossRefGoogle Scholar
  164. 164.
    Pal K, Roy S, Mondal SA et al (2011) Urinary level of CA19–9 as a tumor marker in urothelial carcinoma of the bladder. Urol J 8:203–208PubMedGoogle Scholar
  165. 165.
    Papanicolaou GN, Marshall VF (1945) Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science 101:519–520PubMedCrossRefGoogle Scholar
  166. 166.
    Parker J, Spiess PE (2011) Current and emerging bladder cancer urinary biomarkers. ScientificWorldJournal 11:1103–1112PubMedCrossRefGoogle Scholar
  167. 167.
    Patel NS, Blick C, Kumar PV et al (2009) The diagnostic value of abdominal ultrasound, urine cytology and prostate-specific antigen testing in the lower urinary tract symptoms clinic. Int J Clin Pract 63:1734–1738PubMedCrossRefGoogle Scholar
  168. 168.
    Pavlov IY, Shihab F, Delgado JC (2011) Urine TGF- beta1 assay validation: spinning down urine samples could diminish TGF-beta1 signal. Clin Lab 57:1027–1029PubMedGoogle Scholar
  169. 169.
    Payton S (2012) Bladder cancer: LASP-1-a promising urine marker for detection of bladder cancer. Nat Rev Urol 9:240PubMedCrossRefGoogle Scholar
  170. 170.
    Perazella MA, Coca SG, Hall IE et al (2010) Urine microscopy is associated with severity and worsening of acute kidney injury in hospitalized patients. Clin J Am Soc Nephrol 5:402–408PubMedCrossRefGoogle Scholar
  171. 171.
    Pesch B, Nasterlack M, Eberle F et al (2011) The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines. BJU Int 108:546–552PubMedCrossRefGoogle Scholar
  172. 172.
    Piaton E, Vordos D, Collin-Chavagnac D et al (2010) Cytologie urinaire et marqueurs moleculaires. Ann Pathol 30:112–114PubMedCrossRefGoogle Scholar
  173. 173.
    Pignot G, Bieche I, Vacher S et al (2009) Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker. Eur Urol 56:678–688PubMedCrossRefGoogle Scholar
  174. 174.
    Pillai KR, Jayasree K, Pisharody R et al (2010) Decoy cells in the urine cytology of a renal transplant recipient: an immunohistochemical study. Indian J Pathol Microbiol 53:347–350PubMedCrossRefGoogle Scholar
  175. 175.
    Proctor I, Stoeber K, Williams GH (2010) Biomarkers in bladder cancer. Histopathology 57:1–13PubMedCrossRefGoogle Scholar
  176. 176.
    Protzel C, Hakenberg OW (2010) Molecular markers in the diagnostics and therapy of urothelial cancer. Urologe 49:1415–1424PubMedCrossRefGoogle Scholar
  177. 177.
    Raisi O, Magnani C, Bigiani N et al (2012) The diagnostic reliability of urinary cytology: a retrospective study. Diagn Cytopathol 40:608–614PubMedCrossRefGoogle Scholar
  178. 178.
    Raitanen M-P, Aine R, Rintala E et al (2002) Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol 41:284–289PubMedCrossRefGoogle Scholar
  179. 179.
    Raspollini MR, Comin CE, Crisci A et al (2010) The use of placental S100 (S100P), GATA3 and napsin A in the differential diagnosis of primary adenocarcinoma of the bladder and bladder metastasis from adenocarcinoma of the lung. Pathologica 102:33–35PubMedGoogle Scholar
  180. 180.
    Ratanajaraya C, Nishiyama H, Takahashi M et al (2011) A polymorphism of the POLG2 gene is genetically associated with the invasiveness of urinary bladder cancer in Japanese males. J Hum Genet 56:572–576PubMedCrossRefGoogle Scholar
  181. 181.
    Rathert M (2011) CellPrint in the diagnostics of urothelial carcinoma – an alternative to the cytocentrifuge? In: 27. Tagung der DGZ. Medizinisch Wissenschaftliche Verlagsgesellschaft, Mannheim, S 115–116Google Scholar
  182. 182.
    Rathert P (2003) Urinzytologie beim Harnblasenkarzinom: Kritische Wertung. Urologe 42:908–911PubMedCrossRefGoogle Scholar
  183. 183.
    Rathert P, Rathert M (2011) The wrong „wrong positive“ urine cytology report. In: 27. Tagung der DGZ. Medizinisch Wissenschaftliche Verlagsgesellschaft, Mannheim, S 113–114Google Scholar
  184. 184.
    Rathert P, Roth S (2007) Urinzytologie – Praxis und Atlas, 4. Ausg. Springer, Berlin Heidelberg New YorkGoogle Scholar
  185. 185.
    Renshaw AA (2010) UroVysion, urine cytology, and the College of American Pathologists: where should we go from here? Arch Pathol Lab Med 134:1106–1107PubMedGoogle Scholar
  186. 186.
    Reuschenbach M, Clad A, Von Knebel Doeberitz C et al (2010) Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results. Gynecol Oncol 119:98–105PubMedCrossRefGoogle Scholar
  187. 187.
    Rink M, Chun FK, Minner S et al (2011) Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer. BJU Int 107:1668–1675PubMedCrossRefGoogle Scholar
  188. 188.
    Rosser CJ, Nakamura K, Pendleton J et al (2010) Utility of serial urinalyses and urinary cytology in the evaluation of patients with microscopic haematuria. West Afr J Med 29:384–387PubMedGoogle Scholar
  189. 189.
    Rouprêt M, Wallerand H, Traxer O et al (2010) Checkup and management of upper urinary tract tumours in 2010: an update from the committee of cancer from the French National Association of Urology. Prog Urol 20:260–271PubMedCrossRefGoogle Scholar
  190. 190.
    Rouprêt M, Zigeuner R, Palou J et al (2011) European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 Update. Eur Urol 59:584–594PubMedCrossRefGoogle Scholar
  191. 191.
    Saint F, Quintens H, Rouprêt M et al (2011) Diagnostic test for bladder cancer: the NMP22(R). Prog Urol 21:245–249PubMedCrossRefGoogle Scholar
  192. 192.
    Sakamoto Y, Nishioka J, Noma K et al (2011) Usefulness of survivin/glyceraldehyde-3-phosphate dehydrogenase ratio in urine exfoliated cells for the detection of bladder tumor. Rinsho Byori 59:446–451PubMedGoogle Scholar
  193. 193.
    Sakuma T, Furuta M, Mimura A et al (2011) Urine cytology of micropapillary carcinoma of the urinary bladder. Diagn Cytopathol 39:852–856PubMedCrossRefGoogle Scholar
  194. 194.
    Savic S, Zlobec I, Thalmann GN et al (2009) The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guerin therapy. Int J Cancer 124:2899–2904PubMedCrossRefGoogle Scholar
  195. 195.
    Schlomer BJ, Ho R, Sagalowsky A et al (2010) Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 183:62–67PubMedCrossRefGoogle Scholar
  196. 196.
    Schmitz-Dräger BJ, Tirsar LA, Schmitz-Dräger C et al (2010) Rolle der Immunzytologie in der Abklärung von Patienten mit schmerzloser Makrohämaturie. Urologe 49:741–746PubMedCrossRefGoogle Scholar
  197. 197.
    Schwalb DM, Herr HW, Fair WR (1993) The management of clinically unconfirmed positive urinary cytology. J Urol 150:1751–1756PubMedGoogle Scholar
  198. 198.
    Selvaggi SM (2010) Cytologic detection of concurrent infectious agents in urines from renal transplant patients. Diagn Cytopathol 38:549–550PubMedGoogle Scholar
  199. 199.
    Seripa D, Parrella P, Gallucci M et al (2001) Sensitive detection of transitional cell carcinoma of the bladder by microsatellite analysis of cells exfoliated in urine. Int J Cancer 95:364–369PubMedCrossRefGoogle Scholar
  200. 200.
    Serizawa RR, Ralfkiaer U, Steven K et al (2011) Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events. Int J Cancer 129:78–87PubMedCrossRefGoogle Scholar
  201. 201.
    Shan Z, Wu P, Zheng S et al (2010) Evaluation of upper urinary tract tumors by FISH in Chinese patients. Cancer Genet Cytogenet 203:238–246PubMedCrossRefGoogle Scholar
  202. 202.
    Shariat SF, Chade DC, Karakiewicz PI et al (2010) Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol 183:68–75PubMedCrossRefGoogle Scholar
  203. 203.
    Shariat SF, Savage C, Chromecki TF et al (2011) Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis. Cancer 117:2892–2897PubMedCrossRefGoogle Scholar
  204. 204.
    Shenoy SP, Marla PK, Tantry TP (2011) Re: Feifer et al.: utility of urine cytology in workup of asymptomatic microscopic hematuria in low-risk patients. Urology 77:513–514PubMedCrossRefGoogle Scholar
  205. 205.
    Shidham VB (2007) Appendix II: immunocytochemistry of effusions – processing and commonly used immunomarkers. In: Shidham VB, Atkinson BF (Hrsg.) Cytopathologic diagnosis of serous fluids. Saunders, Philadelphia, pp 237–258Google Scholar
  206. 206.
    Shimada K, Fujii T, Anai S et al (2011) ROS generation via NOX4 and its utility in the cytological diagnosis of urothelial carcinoma of the urinary bladder. BMC Urol 11:22PubMedCrossRefGoogle Scholar
  207. 207.
    Shin YS, Kim SD, Cha JS et al (2011) Clinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer. Int J Urol 18:439–443PubMedCrossRefGoogle Scholar
  208. 208.
    Siddappa S, Mythri K, Kowsalya R (2012) Cytological findings in routine voided urine samples with hematuria from a tertiary care center in south India. J Cytol 29:16–19PubMedCrossRefGoogle Scholar
  209. 209.
    Siddins MT, Wong VV, Fitzgerald JT et al (2011) Challenges in non-muscle invasive bladder cancer: lessons from a regional review. ANZ J Surg 81:889–894PubMedCrossRefGoogle Scholar
  210. 210.
    Singh HK, Donna Thompson B, Nickeleit V (2009) Viral Haufen are urinary biomarkers of polyomavirus nephropathy: new diagnostic strategies utilizing negative staining electron microscopy. Ultrastruct Pathol 33:222–235PubMedCrossRefGoogle Scholar
  211. 211.
    Skoog L, Tani E (2011) Immunocytochemistry: an indispensable technique in routine cytology. Cytopathology 22:215–229PubMedCrossRefGoogle Scholar
  212. 212.
    Smith GD, Bentz JS (2010) „FISHing“ to detect urinary and other cancers: validation of an imaging system to aid in interpretation. Cancer Cytopathol 118:56–64PubMedCrossRefGoogle Scholar
  213. 213.
    Smrkolj T, Mihelic M, Sedlar A et al (2011) Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors. Clin Chem Lab Med 49:311–316PubMedCrossRefGoogle Scholar
  214. 214.
    Soloway MS, Garcia-Roig M, Gorin MA et al (2011) How can we improve outcomes for upper tract urothelial carcinoma? Eur Urol 61:254–256PubMedCrossRefGoogle Scholar
  215. 215.
    Sommerauer M, Jocham D, Laturnus JM (2012) Das nicht muskelinvasive Urothelkarzinom der Harnblase: Neuigkeiten in der Diagnostik und Therapie. Urologe 51:791–797PubMedCrossRefGoogle Scholar
  216. 216.
    Song MJ, Lee HM, Kim SH (2010) Clinical usefulness of fluorescence in situ hybridization for diagnosis and surveillance of bladder cancer. Cancer Genet Cytogenet 198:144–150PubMedCrossRefGoogle Scholar
  217. 217.
    Srinivasan M, Sedmak D, Jewell S (2002) Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol 161:1961–1971PubMedCrossRefGoogle Scholar
  218. 218.
    Srivastava R, Arora VK, Aggarwal S et al (2011) Cytokeratin-20 immunocytochemistry in voided urine cytology and its comparison with nuclear matrix protein-22 and urine cytology in the detection of urothelial carcinoma. Diagn Cytopathol 10.1002/dc.21617Google Scholar
  219. 219.
    Steiner G, Schoenberg MP, Linn JF et al (1997) Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med 3:621–624PubMedCrossRefGoogle Scholar
  220. 220.
    Sternberg I, Rona R, Olsfanger S et al (2011) The clinical significance of class III (suspicious) urine cytology. Cytopathology 22:329–333PubMedCrossRefGoogle Scholar
  221. 221.
    Stoll LM, Johnson MW, Rosenthal DL (2011) High-grade prostatic sarcoma seen in a catheterized urine specimen: case report and differential diagnosis. Diagn Cytopathol 39:762–766PubMedCrossRefGoogle Scholar
  222. 222.
    Straub J, Strittmatter F, Karl A et al (2012) Ureterorenoscopic biopsy and urinary cytology according to the 2004 WHO classification underestimate tumor grading in upper urinary tract urothelial carcinoma. Urol Oncol 10.1016/j.urolonc.2011.12.021Google Scholar
  223. 223.
    Strittmatter F, Buchner A, Karl A et al (2011) Individual learning curve reduces the clinical value of urinary cytology. Clin Genitourin Cancer 9:22–26PubMedCrossRefGoogle Scholar
  224. 224.
    Sullivan PS, Chan JB, Levin MR et al (2010) Urine cytology and adjunct markers for detection and surveillance of bladder cancer. Am J Transl Res 2:412–440PubMedGoogle Scholar
  225. 225.
    Szarvas T, Singer BB, Becker M et al (2011) Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer. BJU Int 107:1069–1073PubMedCrossRefGoogle Scholar
  226. 226.
    Tahoun NS, Abdel Maksoud AM, Mohamed DB (2010) Evaluation of the value of combined urine cytology and cystoscopy for follow-up of superficial transitional cell carcinoma of the urinary bladder. J Egypt Natl Canc Inst 22:105–111PubMedGoogle Scholar
  227. 227.
    Takada S, Yoshikawa M, Hosokawa Y et al (2010) Small cell carcinoma of the urinary bladder detected by urinary cytology: a case report. Hinyokika Kiyo 56:173–175PubMedGoogle Scholar
  228. 228.
    Takao A, Saika T, Uehara S et al (2010) Indications for ureteropyeloscopy based on radiographic findings and urine cytology in detection of upper urinary tract carcinoma. Jpn J Clin Oncol 40:1087–1091PubMedCrossRefGoogle Scholar
  229. 229.
    Tapia C, Glatz K, Obermann EC et al (2011) Evaluation of chromosomal aberrations in patients with benign conditions and reactive changes in urinary cytology. Cancer Cytopathol 119:404–410PubMedCrossRefGoogle Scholar
  230. 230.
    Tauber S, Brunken C, Vierbuchen M (2011) Vorkommen einer p16INK4a-Expression in Zytologien der Harnblase: Ein neuer Weg zur Früherkennung und Verlaufskontrolle beim Urothelkarzinom. Urologe 50:1130–1133PubMedCrossRefGoogle Scholar
  231. 231.
    Terada T (2010) Primary small cell carcinoma of the ureter: a case report involving immunohistochemical and molecular genetic analyses of KIT and PDGFRA genes. Pathology 42:101–102PubMedCrossRefGoogle Scholar
  232. 232.
    Thiryayi SA, Rana DN (2012) Urine cytopathology: challenges, pitfalls, and mimics. Diagn Cytopathol 40:1019–1034PubMedCrossRefGoogle Scholar
  233. 233.
    Tilki D, Burger M, Dalbagni G et al (2011) Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol 60:484–492PubMedCrossRefGoogle Scholar
  234. 234.
    Tilki D, Singer BB, Shariat SF et al (2010) CEACAM1: a novel urinary marker for bladder cancer detection. Eur Urol 57:648–654PubMedCrossRefGoogle Scholar
  235. 235.
    Todenhöfer T, Hennenlotter J, Kuhs U et al (2012) Influence of urinary tract instrumentation and inflammation on the performance of urine markers for the detection of bladder cancer. Urology 79:620–624PubMedCrossRefGoogle Scholar
  236. 236.
    Todenhöfer T, Hennenlotter J, Witstruk M et al (2012) Influence of renal excretory function on the performance of urine based markers to detect bladder cancer. J Urol 187:68–73PubMedCrossRefGoogle Scholar
  237. 237.
    Tritschler S, Karl A, Sommer ML et al (2010) Influence of clinical information on the interpretation of urinary cytology in bladder cancer: how suggestible is a cytologist? BJU Int 106:1165–1168PubMedCrossRefGoogle Scholar
  238. 238.
    Tritschler S, Sommer ML, Straub J et al (2010) Urinary cytology in era of fluorescence endoscopy: redefining the role of an established method with a new reference standard. Urology 76:677–680PubMedCrossRefGoogle Scholar
  239. 239.
    Tschirdewahn S, Boergermann C, Becker M et al (2009) Urinzytologische Diagnostik vor dem Hintergrund der neuen histopathologischen Klassifikation. Urologe 48:615–618PubMedCrossRefGoogle Scholar
  240. 240.
    Tschirdewahn S, vom Dorp F, Rübben H et al (2011) Exfoliative Urinzytologie in der Behandlung der Harnblasenkarzinoms. Urologe 50:292–296PubMedCrossRefGoogle Scholar
  241. 241.
    Turco P, Houssami N, Bulgaresi P et al (2011) Is conventional urinary cytology still reliable for diagnosis of primary bladder carcinoma? Accuracy based on data linkage of a consecutive clinical series and cancer registry. Acta Cytol 55:193–196PubMedCrossRefGoogle Scholar
  242. 242.
    Tyler KL, Selvaggi SM (2011) Morphologic features of prostatic adenocarcinoma on ThinPrep(R) urinary cytology. Diagn Cytopathol 39:101–104PubMedCrossRefGoogle Scholar
  243. 243.
    Ud Din N, Qureshi A, Mansoor S (2011) Utility of p63 immunohistochemical stain in differentiating urothelial carcinomas from adenocarcinomas of prostate. Indian J Pathol Microbiol 54:59–62CrossRefGoogle Scholar
  244. 244.
    Ukimura O (2010) Editorial comment to the clinical significance of urine cytology after a radical cystectomy for urothelial cancer. Int J Urol 17:532–533PubMedCrossRefGoogle Scholar
  245. 245.
    van der Aa MN, Steyerberg EW, Bangma C et al (2010) Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial. J Urol 183:76–80CrossRefGoogle Scholar
  246. 246.
    van Rhijn BWG, van der Poel HG, van der Kwast TH (2009) Cytology and urinary markers for the diagnosis of bladder cancer. Eur Urol 8(Suppl):536–541CrossRefGoogle Scholar
  247. 247.
    Vidas Z, Misić M, Pacić A et al (2010) The value of urinary decoy cells finding in patients with kidney transplantation. Coll Antropol 34:153–157PubMedGoogle Scholar
  248. 248.
    Vojtusek IK, Gracin S, Knotek M et al (2010) First documented case of BK nephropathy in kidney transplant recipient in Croatia: usage of urine cytology in evaluation process. Coll Antropol 34:255–259PubMedGoogle Scholar
  249. 249.
    vom Dorp F, Eisenhardt A, Goebell PJ et al (2009) Harnblasenkarzinom. In: Rübben H (Hrsg) Uroonkologie. Springer, Berlin Heidelberg New York, S 395–476Google Scholar
  250. 250.
    vom Dorp F, Pal P, Tschirdewahn S et al (2011) Correlation of pathological and cytological-cytometric grading of transitional cell carcinoma of the urinary tract. Urol Int 86:36–40CrossRefGoogle Scholar
  251. 251.
    vom Dorp F, Tschirdewahn S, Rübben H (2011) Reevaluation of former G2 urothelial carcinomas in high and low grade tumours by combined cytology and cytometry. In: 27. Tagung der DGZ. Medizinisch Wissenschaftliche Verlagsgesellschaft, Mannheim, S 117–118Google Scholar
  252. 252.
    Voulgaris E, Pentheroudakis G, Pappa L et al (2011) Positive urinary cytology in patients with lung cancer in the absence of obvious urine tract metastases. Lung Cancer 73:51–58PubMedCrossRefGoogle Scholar
  253. 253.
    Vrooman OP, Witjes JA (2010) Follow-up of patients after curative bladder cancer treatment: guidelines vs. practice. Curr Opin Urol 20:437–442PubMedCrossRefGoogle Scholar
  254. 254.
    Vrooman OP, Witjes JA (2008) Urinary markers in bladder cancer. Eur Urol 53:909–916PubMedCrossRefGoogle Scholar
  255. 255.
    Washiya K, Sato T, Miura T et al (2011) Cytologic difference between benignity and malignancy in suspicious cases employing urine cytodiagnosis using a liquid-based method. Anal Quant Cytol Histol 33:169–174PubMedGoogle Scholar
  256. 256.
    Whitson JM, Berry AB, Carroll PR et al (2009) UroVysion testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer. Int Braz J Urol 35:664–671PubMedCrossRefGoogle Scholar
  257. 257.
    Whitworth SA, Subhawong AP, Rosenthal DL et al (2012) Clear cell adenocarcinoma of the lower urinary tract: cytopathologic characteristics and differential diagnoses. Cancer Cytopathol 120(5):308–312PubMedCrossRefGoogle Scholar
  258. 258.
    Wild PJ, Fuchs T, Stoehr R et al (2009) Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis. Cancer Epidemiol Biomarkers Prev 18:1798–1806PubMedCrossRefGoogle Scholar
  259. 259.
    Williamson SR, Montironi R, Lopez-Beltran A et al (2010) Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: the state of the art. Crit Rev Oncol Hematol 76:112–126PubMedCrossRefGoogle Scholar
  260. 260.
    Xu C, Zeng Q, Hou J et al (2011) Utility of a modality combining FISH and cytology in upper tract urothelial carcinoma detection in voided urine samples of Chinese patients. Urology 77:636–641PubMedCrossRefGoogle Scholar
  261. 261.
    Yamada Y, Enokida H, Kojima S et al (2011) MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci 102:522–529PubMedCrossRefGoogle Scholar
  262. 262.
    Yamaguchi T, Kuroda N, Imamura Y et al (2010) Imprint cytologic features of chromophobe renal cell carcinoma morphologically resembling renal oncocytoma: is this an oncocytic variant of chromophobe renal cell carcinoma? Diagn Cytopathol 38:509–513PubMedCrossRefGoogle Scholar
  263. 263.
    Ye YK, Bi XC, He HC et al (2010) CK20 and Ki-67 as significant prognostic factors in human bladder carcinoma. Clin Exp Med 10:153–158PubMedCrossRefGoogle Scholar
  264. 264.
    Yoo JH, Suh B, Park TS et al (2010) Analysis of fluorescence in situ hybridization, mtDNA quantification, and mtDNA sequence for the detection of early bladder cancer. Cancer Genet Cytogenet 198:107–117PubMedCrossRefGoogle Scholar
  265. 265.
    Yoshimine S, Kikuchi E, Matsumoto K et al (2010) The clinical significance of urine cytology after a radical cystectomy for urothelial cancer. Int J Urol 17:527–532PubMedCrossRefGoogle Scholar
  266. 266.
    Youssef RF, Schlomer BJ, Ho R et al (2010) Role of fluorescence in situ hybridization in bladder cancer surveillance of patients with negative cytology. Urol Oncol 30:273–277PubMedGoogle Scholar
  267. 267.
    Zeng Z, Zhou XJ (2010) Detection of bladder cancer by FISH test: a meta-analysis. Zhonghua Bing Li Xue Za Zhi 39:75–78PubMedGoogle Scholar
  268. 268.
    Zhu YP, Shen YJ, Ye DW et al (2012) Narrow-band imaging flexible cystoscopy in the detection of clinically unconfirmed positive urine cytology. Urol Int 88:84–87PubMedCrossRefGoogle Scholar
  269. 269.
    Zuiverloon TC, Nieuweboer AJ, Vekony H et al (2012) Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol 61:128–145PubMedCrossRefGoogle Scholar
  270. 270.
    Zuiverloon TC, van der Aa MN, van der Kwast TH et al (2010) Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clin Cancer Res 16:3011–3018PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • M. Böhm
    • 1
    • 3
    Email author
  • F. vom Dorp
    • 2
  • M. Schostak
    • 1
  • O.W. Hakenberg
    • 4
  • für den Arbeitskreis Urinzytologie der DGU (Deutsche Gesellschaft für Urologie)
  1. 1.Universitätsklinik für Urologie und KinderurologieOtto-von-Guericke UniversitätMagdeburgDeutschland
  2. 2.Klinik und Poliklinik für Urologie, Uroonkologie und KinderurologieUniversitätsklinikum EssenEssenDeutschland
  3. 3.Urologie in den Dill-KlinikenDillenburgDeutschland
  4. 4.Urologische UniversitätsklinikUniversitätsmedizin RostockRostockDeutschland

Personalised recommendations